Research programme: biologics eye disorder therapeutics - ProLynx
Alternative Names: IL-15 - ProLynx; IL-2 - ProLynxLatest Information Update: 19 Mar 2021
At a glance
- Originator Prolynx
- Class Drug conjugates; Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Eye disorders
Most Recent Events
- 09 Mar 2021 Biologics eye disorder therapeutics is available for licensing as of 09 Mar 2021. https://prolynxinc.com/index.html
- 09 Mar 2021 Early research in Eye disorders in USA